Konrad Futyma

Prof. Konrad Futyma

2nd Department of Gynecology, Medical University of Lublin, 20-059 Lublin, Poland
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2009 in European Urology
Verified
Journal Article
Closed access
TRTomasz Rechberger
Tomasz Rechberger
KFKonrad Futyma
Konrad Futyma
KJKatarzyna JANKIEWICZ
Katarzyna JANKIEWICZ
AAAneta Adamiak
Aneta Adamiak
PSPaweł Skorupski
Paweł Skorupski

24 February 2010 in International Urogynecology Journal
Verified
Journal Article
Closed access
PDF file
TRTomasz Rechberger
Tomasz Rechberger
KFKonrad Futyma
Konrad Futyma
KJKatarzyna JANKIEWICZ
Katarzyna JANKIEWICZ
AAAneta Adamiak
Aneta Adamiak
MBMichał Bogusiewicz
Michał Bogusiewicz
PSPaweł Skorupski
Paweł Skorupski

DCDominika Streit- Ciećkiewicz
Dominika Streit- Ciećkiewicz
AKAleksandra Kołodyńska
Aleksandra Kołodyńska
KFKarolina Futyma-Gąbka
Karolina Futyma-Gąbka
MGMagdalena Emilia Grzybowska
Magdalena Emilia Grzybowska
JGJakub Gołacki
Jakub Gołacki
KFKonrad Futyma
Konrad Futyma
Regenerative medicine combines elements of tissue engineering and molecular biology aiming to support the regeneration and repair processes of damaged tissues, cells and organs. The most commonly used preparation in regenerative medicine is platelet rich plasma (PRP) containing numerous growth factors present in platelet granularities. This therapy is increasingly used in various fields of medicine. This article is a review of literature on the use of PRP in gynecology and obstetrics. There is no doubt that the released growth factors and proteins have a beneficial effect on wound healing and regeneration processes. So far, its widest application is in reproductive medicine, especially in cases of thin endometrium, Asherman’s syndrome, or premature ovarian failure (POF) but also in wound healing and lower urinary tract symptoms (LUTS), such as urinary incontinence or recurrent genitourinary fistula auxiliary treatment. Further research is, however, needed to confirm the effectiveness and the possibility of its application in many other disorders.

26 November 2016 in International Urogynecology Journal
Verified
Journal Article
Open access
PDF file
Pawel MiotlaPawel Miotla
Pawel Miotla
RCRufus Cartwright
Rufus Cartwright
KSKatarzyna Skorupska
Katarzyna Skorupska
MBMichal Bogusiewicz
Michal Bogusiewicz
EMEwa Markut-Miotla
Ewa Markut-Miotla
TRTomasz Rechberger
Tomasz Rechberger
Introduction and hypothesis Intravesical onabotulinumtoxinA (Botox) injections are effective for the treatment of idiopathic overactive bladder (OAB) symptoms. The aim of our study was to assess the predisposing factors for urinary retention in women with OAB after intravesical Botox injection. Methods All participants were women of European descent with idiopathic OAB. OnabotulinumtoxinA (100 U) was administered in 20 intra-detrusor injections. Analysis was performed based on the results of safety assessments made during follow-up (FU) visits on weeks 2, 4 and 12, in 208 women who were treated with Botox injections for refractory OAB and who completed all FU visits. Results Women who required clean intermittent self-catheterisation (CISC) and those with post-void residual (PVR) greater than 200 ml were older in comparison with patients with PVR between 50 and 200 ml. Patients who required CISC were also characterised by higher parity and particularly by a higher number of vaginal deliveries. Other factors such as body mass index or comorbidities did not significantly influence PVR and the risk of CISC. Conclusions Elderly and/or multiparous women are at increased risk of urinary retention after intravesical 100-U Botox injections. The risk of new onset urine retention in our study has completely disappeared 2 weeks after Botox injections. Based on our results of the way in which the PVRs have changed over time, we can conclude that OAB patients should be optimally assessed during the first 2 weeks after Botox injections.

12 September 2015 in International Urogynecology Journal
Verified
Journal Article
Open access
PDF file
Pawel MiotlaPawel Miotla
Pawel Miotla
KFKonrad Futyma
Konrad Futyma
RCRufus Cartwright
Rufus Cartwright
MBMichal Bogusiewicz
Michal Bogusiewicz
KSKatarzyna Skorupska
Katarzyna Skorupska
TRTomasz Rechberger
Tomasz Rechberger
Intravesical onabotulinumtoxinA (Botox®) is effective for idiopathic overactive bladder (OAB) symptoms. Our primary objective was to compare the efficacy of onabotulinumtoxinA for women with de novo OAB after midurethral sling (MUS) surgery and women with idiopathic OAB.

30 September 2016 in Ginekologia Polska
Verified
Journal Article
Open access
KFKonrad Futyma
Konrad Futyma
KGKrzysztof Gałczyński
Krzysztof Gałczyński
KRKatarzyna Romanek
Katarzyna Romanek
AFAleksandra Filipczak
Aleksandra Filipczak
TRTomasz Rechberger
Tomasz Rechberger
The reported number of cesarean sections in Poland is approximately 30% and is associated with increasing number of early and late complications. The myometrial discontinuity at the site of previous cesarean section is known in the literature as "isthmocoele", "niche", "pouch" or cesarean scar defect. In most cases presence of isthmocoele has no clinical significance, but in some patients it may cause abnormal uterine bleeding, dysmenorrhea, dyspareunia, pelvic pain or be associated with secondary infertility. This defect may be treated by laparoscopy, hysteroscopy or vaginal surgery.